Review and evaluation of treatment procedures using injectable poly-l-lactic acid in the treatment of human immunodeficiency virus-associated facial lipoatrophy

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 12, 2010, Pages 43-49

  Mest, Douglas ^a   Humble, Gail ^a  

^a Blue Pacific Aesthetic Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID;

ARTICLE; HEALTH CARE ORGANIZATION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; INJECTION; LIPOATROPHY; MEDICAL INFORMATION; NEEDLE; PAPULE; PRACTICE GUIDELINE;

EID: 78650404394     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sculptra [package insert]. Bridgewater, NJ: Dermik Laboratories, a business of Sanofi-Aventis U.S., LLC; 2006.
2. Burgess CM. Treatment of facial asymmetry with poly-L-lactic acid: a case study. Aesthetic Plast Surg. 2008;32(3):552-554.
3. Sculptra Aesthetic [package insert]. Bridgewater, NJ: Dermik Laboratories, a business of sanofi-aventis U.S., LLC; 2009.
4. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in-vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res. 1993;27(9):1135-1148.
5. De Jong WH, Eelco Bergsma J, Robinson JE, Bos RR. Tissue response to partially in-vitro predegraded poly-L-lactide implants. Biomaterials. 2005;26(14):1781-1791.
6. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52(2):233-239.
7. Cattelan AM, Bauer U, Trevenzoli M, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol. 2006;142(3):329-334.
8. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg. 2006;32(11):1336-1345.
9. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5(2):82-87.
10. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7(3):181-185.
11. Alam M, Gladstone H, Kramer EM, et al. ASDS guidelines of care: injectable fillers. Dermatol Surg. 2008;34(suppl 1): S115-S148.
12. Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol. 2004;3(4):385-389.
13. Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol. 2007;6(2):123-128.
14. Mest DR, Humble GM. Retreatment with injectable poly-L-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg. 2009;35(Suppl 1):350-359.
15. Mest DR, Humble GM. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Aesthetic Plast Surg. 2009;33(4):654-656.
16. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17(17):2471-2477.
17. Onesti MG, Renzi LF, Paoletti F, Scuderi N. Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART). Acta Chir Plast. 2004;46(1):12-15.
18. Guaraldi G, Orlando G, DeFazio D, et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther. 2005;10(6):753-759.
19. Lafaurie M, Dolivo M, Porcher R, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38(4):393-398.
20. Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol. 2005;18(6):273-278